Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,552
datasets available to search
ShareScore release 0.9.0
Dataset results
2,552 results for “Glioblastoma”
Dataset related to article "Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment"
<p>This record contains raw data related to article "Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment"</p> <p>ABSTRACT:</p> <p>BACKGROUND: The incidence of glioblastoma among elderly patients is constantly increasing. The value of radiation therapy and concurrent/adjuvant chemotherapy has been widely assessed. So far, the role of surgery has not been thoroughly investigated. The study aimed to evaluate safety and impact of several entities of surgical resection on outcome of elderly patients with newly diagnosed glioblastoma treated by a multimodal approach.</p> <p>METHODS:</p> <p>Patients ≥ 65 years, underwent surgery were included. The extent of surgical resection (EOR) was defined as complete resection (CR = 100%), gross total resection (GTR = 90-99%), sub-total resection (STR = 78-90%), partial resection (PR = 30-78%), and biopsy. After surgery, all patients received adjuvant radiotherapy (60/2 Gy fraction) with concomitant/adjuvant temozolomide chemotherapy.</p> <p>RESULTS:</p> <p>From March 2004 to December 2015, 178 elderly with a median age of 71 years (range 65-83 years) were treated. CR was obtained in 8 (4.5%), GTR in 63 (35.4%), STR in 46 (25.8%), PR in 16 (9.0%), and biopsy in 45 (25.3%). RT was started in all patients, concurrent/adjuvant CHT in 149 (83.7%) and 132 (74.2%). The median follow-up time was 12.2 months (range 0.4-50.4 months). The median, 1- and 2-year progression-free survival was 8.9 months (95%CI 7.8-100 months), 32.0 ± 3.5%, and 12.9 ± 2.6%. The median, 1- and 2-year overall survival were 12.2 (95%CI 11.3-13.1 months), 51.1 ± 3.7%, and 16.3 ± 2.9%. Tumor location, extent of resection, and neurological status after surgery statistically affected survival (p ≪ 0.01).</p> <p>CONCLUSION:</p> <p>Maximal surgical resection is safe and feasible in elderly patients with influence on survival. A preoperative evaluation has to be carried out.</p>
Dataset related to article "Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis"
<p>This record contains raw data related to article "Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis"</p> <p>The current treatment for newly diagnosed glioblastoma consists of surgery followed by conventional radiotherapy (CRT) with concomitant and adjuvant chemotherapy. Hypofractionated radiation therapy (HFRT) has been investigated and it resulted feasible and safe. The aim of this study was to evaluate whether HFRT can be comparable to CRT.</p> <p>MATERIALS AND METHODS:</p> <p>The analysis included newly diagnosed glioblastoma patients treated with CRT 60 Gy/30 fractions or HFRT 60 Gy/15 fractions. A propensity score matching analysis (PSM) was performed using a logistic regression that considered age, KPS, extent of surgery, MGMT and IDH status.</p> <p>RESULTS:</p> <p>A total of 267 patients were included; before PSM 169 were in CRT-group and 98 in HRFT-group. After 1:1 matching, 82 patients resulted in each group. The median OS time was 17.9 months for the CRT-group and 16.7 months for the HFRT-group; the 1, 2, 3-year OS rates were 75.6%, 32.7%, and 15.5% for the CRT-group, and 75.6%, 33.3%, and 18.9% for the HFRT-group (p value = 0.8). No statistically significant differences were recorded between the two radiation therapy treatments performed.</p> <p>CONCLUSIONS:</p> <p>A short course of radiation therapy would seem comparable to CRT in terms of outcome and less burdensome for these poor prognosis patients.</p> <p> </p>
Dataset related to article "Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis"
<p>This record contains raw data related to article "Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis"</p> <p>OBJECTIVE::</p> <p>To evaluate hypofractionated radiation therapy (HFRT) given at therapeutic effective doses in a phase II study. Endpoints were progression-free survival (PFS) rate, overall survival (OS), and incidence of toxicity.</p> <p>METHODS::</p> <p>Patients with newly diagnosed glioblastoma, age ⩾70 years, Karnofsky performance scale (KPS) score ⩽60, were enrolled. The total dose of HFRT was 52.5 Gy/15 fractions, corresponded to a biological effective dose to the tumor of 70.88 Gy.</p> <p>RESULTS::</p> <p>Thirty patients were treated, with a median age of 75 years. Concurrent and adjuvant temozolomide chemotherapy (TMZ-CHT) was administered in 7 (23.3%) and 11 (40.7%) patients received only adjuvant TMZ-CHT. The median, 6-month PFS, and 12-month PFS were 5.0 months, 43.3%, and 20%, respectively. The median, 6-month OS, and 12-month OS were 8 months, 90%, and 30%, respectively. At the last observation time, 26 patients (86.7%) were dead and 4 (13.3%) were alive. No increase in steroid drugs was required during radiotherapy treatment and a reduction was possible in 12 (40%). Patients with KPS=60, RPA V, MGMT methylated status, neurological status stable or improved after surgery and who underwent HFRT with concurrent and adjuvant CHT, had the better outcome.</p> <p>CONCLUSION::</p> <p>HFRT has proven to be feasible and effective, with limited morbidity, for selected elderly and frail patients with newly diagnosed glioblastoma. The primary objective of this study was not reached in the whole cohort but only in selected patients, who need more aggressive treatment.</p>
Fig. 2 in Cassane diterpenoids from the aerial parts of Caesalpinia pulcherrima and their antibacterial and anti-glioblastoma activity
Fig. 2. Key HMBC correlations of compounds 1–5 and 7.
Single-cell RNA-seq characterization of glioblastoma
GEO Series GSE224090. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
Dll1 acts as a tumor suppressor in neural stem cells to induce an astroglial lineage-restricted glioblastoma
GEO Series GSE32293. Mus musculus. 4 samples. Type: Expression profiling by array.
The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells [RNA-seq]
GEO Series GSE158740. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
The RNA polymerase II subunit B gene(POLR2B) functions as a growth regulator in human glioblastoma
GEO Series GSE192823. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
A blueprint for local and distal glioblastoma invasion programs
GEO Series GSE281796. Homo sapiens. 23 samples. Type: Expression profiling by high throughput sequencing; Other.
Multiregional sampling of primary glioblastoma specimens
GEO Series GSE226726. Homo sapiens. 11 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Synthetic Lethal Interaction Between Loss of Function of OGDH and Bcl-xL in Glioblastoma
GEO Series GSE223297. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
Polysome profiling of a human glioblastoma reveals intratumoral heterogeneity
GEO Series GSE130220. Homo sapiens. 24 samples. Type: Expression profiling by array.
RNA-seq of glioblastoma stem cells with CCL21 treatment
GEO Series GSE178337. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Identification of Human Pluripotent Stem Cell Derived Astrocytic Progenitors that Correlate with Glioblastoma Subtypes
GEO Series GSE226740. Homo sapiens. 2 samples. Type: Expression profiling by high throughput sequencing.
Microenvironment T-Type calcium channels regulate neuronal and glial processes in glioblastoma
GEO Series GSE273629. Mus musculus. 2 samples. Type: Expression profiling by high throughput sequencing.
Global transcriptional profiling changes upon knockdown of LKB1 in human glioblastoma cell lines
GEO Series GSE91016. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
Methylome analysis for prediction of long and short survival in glioblastoma patients from the Nordic phase 3 trial
GEO Series GSE207426. Homo sapiens. 59 samples. Type: Methylation profiling by array.
mRNA, lncRNA and microRNA expression profiling in human brain glioblastoma
GEO Series GSE103229. Rattus norvegicus; Mus musculus; Homo sapiens. 20 samples. Type: Expression profiling by array; Non-coding RNA profiling by array.
TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO
GEO Series GSE236661. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
SPRK1 shRNA and overexpression followed by RNA-seq in glioblastoma cells
GEO Series GSE203177. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.